516 related articles for article (PubMed ID: 11600818)
1. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide for the treatment of acute myeloid leukemia.
Steins MB; Bieker R; Padró T; Kessler T; Kienast J; Berdel WE; Mesters RM
Leuk Lymphoma; 2003 Sep; 44(9):1489-93. PubMed ID: 14565649
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of thalidomide in patients with acute myeloid leukemia.
Steins MB; Padró T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM
Blood; 2002 Feb; 99(3):834-9. PubMed ID: 11806984
[TBL] [Abstract][Full Text] [Related]
4. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
5. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W; Mesters R; Tinnefeld H; Loges S; Staib P; Duhrsen U; Flasshove M; Ottmann OG; Jung W; Cavalli F; Kuse R; Thomalla J; Serve H; O'Farrell AM; Jacobs M; Brega NM; Scigalla P; Hossfeld DK; Berdel WE
Blood; 2003 Oct; 102(8):2763-7. PubMed ID: 12843001
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in hematologic malignancies.
Moehler TM; Ho AD; Goldschmidt H; Barlogie B
Crit Rev Oncol Hematol; 2003 Mar; 45(3):227-44. PubMed ID: 12633837
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
Padró T; Bieker R; Ruiz S; Steins M; Retzlaff S; Bürger H; Büchner T; Kessler T; Herrera F; Kienast J; Müller-Tidow C; Serve H; Berdel WE; Mesters RM
Leukemia; 2002 Jul; 16(7):1302-10. PubMed ID: 12094254
[TBL] [Abstract][Full Text] [Related]
8. [Dynamic observation of vascular endothelial growth factor (VEGF)/VEGF-receptors expression in acute leukemia].
Wang C; Chen FY; Zhu JS; Xu YP; Han JY; Ouyang RR
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):845-8. PubMed ID: 15634546
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy in hematologic malignancies.
Moehler TM; Hillengass J; Goldschmidt H; Ho AD
Curr Pharm Des; 2004; 10(11):1221-34. PubMed ID: 15078137
[TBL] [Abstract][Full Text] [Related]
10. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
11. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H
Br J Haematol; 2003 Nov; 123(3):436-41. PubMed ID: 14617002
[TBL] [Abstract][Full Text] [Related]
12. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
13. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
14. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies.
Rajkumar SV; Mesa RA; Tefferi A
J Hematother Stem Cell Res; 2002 Feb; 11(1):33-47. PubMed ID: 11847002
[TBL] [Abstract][Full Text] [Related]
15. Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: a single center study.
Todorovic M; Radisavljevic Z; Balint B; Andjelic B; Todorovic V; Jovanovic MP; Mihaljevic B
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):488-93. PubMed ID: 22417860
[TBL] [Abstract][Full Text] [Related]
16. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Karp JE; Gojo I; Pili R; Gocke CD; Greer J; Guo C; Qian D; Morris L; Tidwell M; Chen H; Zwiebel J
Clin Cancer Res; 2004 Jun; 10(11):3577-85. PubMed ID: 15173063
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide.
Kreuter M; Steins M; Woelke K; Buechner T; Berdel WE; Mesters RM
Eur J Haematol; 2007 Nov; 79(5):392-7. PubMed ID: 17916085
[TBL] [Abstract][Full Text] [Related]
18. Role of angiogenesis inhibitors in acute myeloid leukemia.
Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE
Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083
[TBL] [Abstract][Full Text] [Related]
19. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
Padró T; Ruiz S; Bieker R; Bürger H; Steins M; Kienast J; Büchner T; Berdel WE; Mesters RM
Blood; 2000 Apr; 95(8):2637-44. PubMed ID: 10753845
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
